Cell biotech has declared a new vision in celebration of its 30th anniversary. The company outlined its strategic direction to become a leader in driving next-generation innovation in the global healthcare market and pledged a new leap forward with its employees.
Founded in 1995, Cell biotech is Korea’s first-generation biotech company. It became the fifth company globally and the first in Korea to successfully mass-produce lactic acid bacteria, achieving the domestication of probiotics. The company also developed the world’s first dual-coating technology and registered it as a global patent, proving the competitive edge of its CBT probiotics not only in Korea but also in the global market. The self-developed “CBT probiotics” have been internationally recognized for their excellence and safety by being registered as the most FDA GRAS(Generally Recognized as Safe) ingredients in the world.
Cell biotech expanded its brand portfolio with the lactic acid bacteria brand “DUOLAC,” followed by microbiome skincare “LACTOClear” and enhanced absorption nutritional supplements under the brand “DUOLAB.” The company continuously ensures safety beyond domestic standards with certifications such as GMP, ISO 9001, ISO 14001, HACCP, and HALAL, maintaining a global standard management system. Thanks to its technological capabilities, Cell biotech has ranked first in global probiotic exports for 11 consecutive years and has solidified its position as Korea’s leading microbiome pioneer, exporting probiotics products and raw materials to more than 55 countries.
In celebration of its 30th anniversary, Cell biotech has announced its mid- to long-term vision under the goal of becoming a “Global Biopharma Innovator for a Healthy Future.” The company plans to become a biopharmaceutical company by 2025 and aims to grow into a global big pharma leader in the microbiome-based drug market by 2055. To achieve this, Cell biotech will focus on developing microbiome-based new drugs for diseases such as colon cancer and obesity, and will expand its CDMO business specialized in microbiomes centered around probiotics.
Additionally, Cell biotech will strengthen the safety and functionality of its DUOLAC brand to solidify its leadership in the domestic probiotic market. The company also plans to expand its position as a global raw material supplier by increasing the supply of CBT probiotics. It will explore new functional probiotic markets through the development of individually recognized CBT probiotics and diversify its business areas into cosmetics, fertilizers, and food products using probiotics, fostering sustainable growth.
A Cell biotech representative stated, “Over the past 30 years, we have led the globalization of K-probiotics based on research and trust.” The company added, “In the future, Cell biotech will continue to strengthen its position as a biopharma company through research and technological innovation. Through probiotics-based solutions, we aim to enhance global health and quality of life. We will lead innovative solutions using probiotics, including a colon cancer drug, and strive to improve the health and lives of people around the world.”